Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis
Today, we announced a £1.17 million grant to support a randomized controlled trial at the
@UniofOxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P).
“This study is an important step forward in understanding the potential of ketogenic therapy on physical and mental health in this highly vulnerable patient group,” said
@janellison, co-founder and president of Baszucki Group. “This ambitious project represents a rare opportunity to gain a deeper understanding of how ketogenic therapy could fundamentally transform the trajectory of serious mental illness in a largely medication-naive population. We are thrilled to support the research team at Oxford in this first-of-its-kind trial.”
Read the full press release:
bit.ly/3RlXpE0